• Beta Bionics Chief Commercial Officer Mark Hopman sold 275 common shares on June 4 at $12.31.
• Directly held stake fell to 130,612 shares following the transaction.
• Sale was executed under a Rule 10b5-1 trading plan adopted May 13, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002048497-26-000008), on June 05, 2026, and is solely responsible for the information contained therein.